777 results about "Esophageal tube" patented technology

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.

Methods and apparatus for treating gastroesophageal reflex and other luminal conditions provide for delivering acoustic energy to a body lumen to remodel tissue surrounding the body lumen. In the case of treating GERD, a catheter carrying an ultrasonic or other vibrational transducer is introduced to the lower esophageal sphincter, and acoustic energy is delivered to the sphincter in order to tighten or bulk the sphincter such that reflex is reduced.

Method for screening patients to predict which patients at risk of a medical disorder, such as morbid obesity, gastrointestinal problems, or gastroesophageal problems, will be responders, and conversely, which patients will not, to achieve a favorable outcome from therapy for that disorder. This method supports an intervention strategy for patients having weight or gastrointestinal problems that will cut health costs. It enables patients and care-givers alike to more efficiently use their time, efforts and resources by enabling an early selection of an appropriate treatment modality for a given patient. Its application also extends to other implantable medical devices and therapies using them.

A tracheo-oesophageal fistula catheter (1) comprises an elongate conduit (2) having a proximal and a distal end, the conduit (2) comprising a plurality of lumens commencing adjacent to the proximal end; means (8, 9) for substantially sealing a tracheo-oesophageal fistula, the means being attached to the conduit (2) adjacent to the proximal end and comprising two elements (8, 9) to be placed on either side of the fistula; and at least one expandable balloon (7) attached to the conduit (2) adjacent to the distal end, and in fluid connection with at least one of said lumens; wherein at least one lumen is a gastric lumen, the gastric lumen extending along the full length of the conduit and having an outlet (6) at the distal end of the conduit (2), and wherein at least one element of the means for sealing the fistula comprises an expandable balloon in fluid connection with at least one of said lumens.

The present specification discloses devices and methodologies for the treatment of transient lower esophageal sphincter relaxations (tLESRs). Individuals with tLESRs may be treated by implanting a stimulation device within the patient's lower esophageal sphincter and applying electrical stimulation to the patient's lower esophageal sphincter, in accordance with certain predefined protocols. The presently disclosed devices have a simplified design because they do not require sensing systems capable of sensing when a person is engaged in a wet swallow and have improved energy storage requirements.

The present invention provides compositions for treatment of gastro-esophageal reflux disorders. The compositions include at least two of the following: (i) one or more digestive enzymes; (ii) one or more probiotics; and (iii) stevia. Also provided are processes for preparing the compositions useful for treatment of gastro-esophageal reflux disorders, and methods of treating subjects against gastro-esophageal reflux disorders, which include administering to a subject a therapeutically effective amount of the compositions of the present invention.

A medical device is provided for insertion into a cavity of a patient to visual the internal membranes of the patient. The medical device can be an endotracheal tube, a suction tube, a bronchoscope, a tube changer, an esophageal tube, an intubating tube, an esophageal tube in combination with a separate intubating tube, a device for manipulating the position of the epiglottis of the patient, a stylet, or a tube insertable into the vagina of the patient. The medical device has a camera lumen having a sealed window at one end thereof attached thereto, and a separate camera which is insertable into the camera lumen and is removable from the camera lumen. The camera is used to monitor the internal membranes of the patient during the medical procedure.

The invention discloses a compound or its salt shown in the formula (I) and usage of the compound as a potassium competitive acid blocker or a gastric acid secretion inhibitor. The compound has a proton pump (H+/K+)-ATPase inhibitory effect and can be used for preventing, treating and inhibiting diseases related to gastric acid secretion, such as peptic ulcer, zollinger-ellison syndromes, gastritis, erosive esophagitis, reflux esophagitis and symptomatic gastroesophageal reflux diseases.

The invention relates to a supporting frame capable of being taken out. In the invention, a sandwich structure that a support is arranged between an inner membrane and an outer membrane is adopted; the connection part of the inner membrane and the outer membrane is opposite to a mesh of the supporting frame; and the supporting frame can freely wriggle in the space formed by the disconnection part of the inner membrane and the outer membrane, therefore, the supporting frame capable of being taken out, provided by the invention, has particularly good flexibility; a full covering membrane structure is adopted to ensure that granulation tissues cannot grow into the supporting frame; and a detachable design is adopted to ensure that the supporting frame can be conveniently taken out. The supporting frame capable of being taken out can be used for inducing and promoting the growth of a neonatal cavity tube, the covering and the epithelization of a mucous membrane, can be conveniently taken out and detached under the direct vision of an endoscopy after the mucous membrane of the neonatal cavity tube is epithelized and the organization is stable, and can be used for a temporary support under the situations of esophagus rebuilding and injury repairing, trachea rebuilding and injury repairing, urethra rebuilding and injury repairing, esophagus-esophagus anastomosing, intestine-intestine anastomosing, nasal cavity rebuilding and injury repairing, external auditory canal rebuilding and injury repairing and the like.

Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

To deliver a medication and its active ingredients to the esophagus, a nasal irrigator, which is capable of delivering medicated fluid that coats the whole nasal and paranasal sinus cavities, is used. The nasal irrigator forces an aerosol mist of the medicated fluid into the nasal cavity above the inferior turbinate, independent of a user's breathing in. Mucociliary clearance from the nasal cavity then delivers the medication to the throat and it is then topically introduced onto the esophagus over an extended period of time.

A dual bladed laryngoscope for quickly and easily intubating a patient. The invention has two blades pivotally hinged on one side while the opposing side is open allowing the laryngoscope to be easily removed after intubating a patient. The proximal end of the upper blade has a grip portion which can be moved closer to or farther away from the handle attached to the proximal end of the lower blade to open or close the distal ends of the lower and upper blades. The lower blade of the invention has a distal end adapted as an esophageal obturator for obstructing the esophagus. An arytenoid bumper to prevent the laryngoscope from penetrating too far into the esophagus is preferably secured to the distal end of the lower blade. The arytenoid bumper may have a ramp or wedge shape adapted to deflect an intubation tube through a patient's larynx and into the trachea. The upper blade optionally has a tongue guard adapted to hold the tongue outside of a channel formed by the lower blade, the tongue guard and the upper blade. A suction conduit is optionally built in or secured to either the lower blade or the upper blade for providing a tube for suctioning secretions or emesis. A suction break is located in the handle of the laryngoscope to allow a finger of the hand holding the laryngoscope to control the presence and intensity of suction.

The development and construction of implantable artificial organs, and a process for manufacturing three-dimensional polymer microscale and nanoscale structures for use as scaffolds in the growth of biological structures such as hollow organs, luminal structures, or other structures within the body are disclosed.

The invention provides a primary cell culture medium for culturing primary esophageal squamous carcinoma epithelial cells and containing a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor, and a culture method using the primary cell culture medium. According to the culture method, the primary cells are cultured on a culture vessel coated with extracellular matrigel by using the primary cell culture medium, so that the primary cells are rapidly proliferated. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for evaluating and screening curative effects of medicines.